IVVD Share Price Performance
US$0.80
-0.49 (-38.19%)
92.0% undervalued intrinsic discount
US$10.00
Fair Value
Price US$0.80
AnalystConsensusTarget US$10.00
AnalystHighTarget US$5.00
AnalystLowTarget US$1.00
Fair ValueUS$10.00
Share Pricen/a
Invivyd, Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 104 Fair Values set on narratives written by author
IVVD Community Narratives
AN
Fair Value
·Fair Value US$10 92.0% undervalued intrinsic discount
Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update
0users have liked this narrative
0users have commented on this narrative
43users have followed this narrative
AN
Fair Value
·Fair Value US$5 84.1% undervalued intrinsic discount
Rapid Antibody Advances Will Leverage Secular Pandemic Trends
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$1 20.3% undervalued intrinsic discount
Regulatory Risks And Competition Will Impede Gains But Yield Promise
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Invivyd
92.0% undervalued intrinsic discount
Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update
View narrativeAN
Updated 23 Jun
Invivyd
20.3% undervalued intrinsic discount
Regulatory Risks And Competition Will Impede Gains But Yield Promise
View narrativeAN
Published 22 Aug 2025
Invivyd
84.1% undervalued intrinsic discount
Rapid Antibody Advances Will Leverage Secular Pandemic Trends
View narrativeAN
Published 21 Aug 2025
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
IVVD: Phase 3 Prophylaxis Readouts And BLA Prospect Will Drive Upside
Fair Value: US$10 92.0% undervalued intrinsic discount
43 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory Risks And Competition Will Impede Gains But Yield Promise
Fair Value: US$1 20.3% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rapid Antibody Advances Will Leverage Secular Pandemic Trends
Fair Value: US$5 84.1% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Invivyd, Inc. Key Details
About IVVD
- Founded
- 2020
- Employees
- 122
- CEO
- WebsiteView website
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
